40505-51-9

Basic information

• Product Name: 4-(2-METHOXYPHENYL)CYCLOHEXANONE
• Synonyms: 4-(2-METHOXYPHENYL)CYCLOHEXANONE;4-(2-methoxyphenyl)cyclohexan-1-one
• CAS NO: 40505-51-9
• Molecular Formula: C₁₃H₁₆O₂
• Molecular Weight: 204.267
• Mol File: 40505-51-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 322.7±42.0 °C(Predicted)
• Appearance: /
• Density: 1.068±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 4-(2-METHOXYPHENYL)CYCLOHEXANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-METHOXYPHENYL)CYCLOHEXANONE(40505-51-9)
• EPA Substance Registry System: 4-(2-METHOXYPHENYL)CYCLOHEXANONE(40505-51-9)

Safety Data

• Hazardous Substances Data: 40505-51-9(Hazardous Substances Data)

Upstream product

• 578-57-4 2-bromoanisole 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 167851-45-8 8-(2-methoxyphenyl)-1,4-dioxa-spiro[4.5]decan-8-ol 
• 170011-47-9 1,4-dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate 
• 5720-06-9 2-Methoxyphenylboronic acid 
• 218776-48-8 4-(2-Methoxy-phenyl)-cyclohex-2-enone 
• 16750-63-3 2-methoxyphenylmagnesium bromide 
• 13482-22-9 4-hydroxycyclohexanone 
• 40503-84-2 4-hydroxy-4-(2-methoxy-phenyl)-cyclohexanone 

Relevant articles and documents

Cobalt-Catalyzed Desymmetric Isomerization of Exocyclic Olefins

Chiral cyclic olefins, 1-methylcyclohexenes, are versatile building blocks for the synthesis of pharmaceuticals and natural products. Despite the prevalence of these structural motifs, the development of efficient synthetic methods remains an unmet challenge. Herein we report a novel desymmetric isomerization of exocyclic olefins using a series of newly designed chiral cobalt catalysts, which enables a straightforward construction of chiral 1-methylcyclohexenes with diversified functionalities. The synthetic utility of this methodology is highlighted by a concise and enantioselective synthesis of a natural product, β-bisabolene. The versatility of the reaction products is further demonstrated by multifarious derivatizations.

Optimization of TRPV6 calcium channel inhibitors using a 3D ligand-based virtual screening method

Herein, we report the discovery of the first potent and selective inhibitor of TRPV6, a calcium channel overexpressed in breast and prostate cancer, and its use to test the effect of blocking TRPV6-mediated Ca2+-influx on cell growth. The inhib

Alpha 1a adrenergic receptor antagonists

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.